drugset / Trial / NCT02399735

Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation

NCT02399735

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to explore the safety of NK cells from Sibship in patients with recurrent hepatocellular carcinoma after liver transplantation.

Timeline

Start
2014-10
Primary completion
2018-06
Completion
2018-06

Drugs

EvaluationDrugModalityDoseRoute
Subject TROCULEUCEL Cell therapy 5e+09 cells
Subject TROCULEUCEL Cell therapy 1e+10 cells